Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirelizumab with Chemoradiation for Unresectable Gastric Cancer
NCT05528367Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05528367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528367.